Format

Send to

Choose Destination
J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S33-8. doi: 10.1097/QAI.0b013e3182097537.

Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.

Author information

1
Departments of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520-8093, USA. david.fiellin@yale.edu

Abstract

BACKGROUND:

Buprenorphine/naloxone allows the integration of opioid dependence and HIV treatment.

METHODS:

We conducted a prospective study in HIV-infected opioid-dependent patients to investigate the impact of buprenorphine/naloxone treatment on drug use. Self-report and chart review assessments were conducted every 3 months (quarters 1-4) for 1 year. Outcomes were buprenorphine/naloxone treatment retention, drug use, and addiction treatment processes.

RESULTS:

Among 303 patients enrolled between July 2005 and December 2007, retention in buprenorphine/naloxone treatment was 74%, 67%, 59%, and 49% during Quarters 1, 2, 3, and 4, respectively. Past 30-day illicit opioid use decreased from 84% of patients at baseline to 42% in retained patients over the year. Patients were 52% less likely to use illicit opioids for each quarter in treatment (Odds ratio = 0.66; 95% CI: 0.61 to 0.72). Buprenorphine/naloxone doses and office visits approximated guidelines published by the United States Department of Health and Human Services. Urine toxicology monitoring was less frequent than recommended.

CONCLUSIONS:

Buprenorphine/naloxone provided in HIV treatment settings can decrease opioid use. Strategies are needed to improve retention and address ongoing drug use in this treatment population.

PMID:
21317592
PMCID:
PMC3863630
DOI:
10.1097/QAI.0b013e3182097537
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center